v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
CURRENT ASSETS    
Cash $ 1,254,903 $ 96,391
Prepaid expenses 94,585
Due from Chromocell Corporation 40,400
Deferred offering costs 750,000
TOTAL CURRENT ASSETS 2,139,888 96,391
TOTAL ASSETS 2,139,888 96,391
CURRENT LIABILITIES    
Accounts payable and accrued expenses 1,279,487 4,620,925
Accrued compensation 308 645,947
Bridge loan, net of debt discount 316,324
Loan payable, net of debt discount 2,155,719 202,279
Loan payable - related party, net of debt discount 131,868 750,082
Due to Chromocell Corporation 5,386
TOTAL CURRENT LIABILITIES 3,567,382 6,540,943
TOTAL LIABILITIES 3,567,382 6,540,943
STOCKHOLDERS’ DEFICIT    
Common stock, $0.0001 par value, 200,000,000 shares authorized, 5,818,111 and 3,906,300 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 583 391
Additional paid in capital 18,120,176 7,074,646
Accumulated deficit (19,548,253) (13,519,649)
TOTAL STOCKHOLDERS’ DEFICIT (1,427,494) (6,444,552)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 2,139,888 96,391
Series A Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value, issued 60
TOTAL STOCKHOLDERS’ DEFICIT 60
Series C Preferred Stock [Member]    
STOCKHOLDERS’ DEFICIT    
Preferred stock, value, issued
TOTAL STOCKHOLDERS’ DEFICIT

Source